Oncology Focus : CAR-T and CAR-NK therapies represent ~30% of all cell and gene trials, with a strong focus on solid and hematological malignancies. Significant attention on gastrointestinal tract and ...

for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase ...

However, they also respond more quickly to treatment, according to Cleveland Clinic. The most common type is diffuse large ...